Kymera Therapeutics (KYMR) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Chairperson welcomed attendees, introduced board members, executive team, and independent auditor.
Outlined meeting procedures and confirmed agenda as set forth in the 2024 Notice of Annual Meeting and Proxy Statement.
Board and executive committee updates
Introduced all board members and executive officers present at the meeting.
Shareholder proposals
Four proposals presented: election of Class I Directors, advisory vote on executive compensation, ratification of independent auditor, and amendment to the 2020 Stock Option and Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kymera Therapeutics
- Advancing oral immunology therapies with robust pipeline and strong financial runway.KYMR
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - KT-621 and IRF5 programs advance, with pivotal data and new pipeline disclosures expected in 2027.KYMRLeerink Global Healthcare Conference 202610 Mar 2026
- Phase 2B trials for KT-621 advance, with rapid efficacy and new IRF5 programs targeting lupus.KYMRTD Cowen 46th Annual Health Care Conference3 Mar 2026
- STAT6 and IRF5 programs advance with strong data, targeting major unmet needs in immunology.KYMROppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
- Advanced pipeline, strong cash reserves, and higher R&D spending led to a larger net loss.KYMRQ4 202526 Feb 2026
- Oral degraders show strong potential to redefine immunology treatment for millions.KYMRCorporate presentation26 Feb 2026
- Oral therapies with biologics-like efficacy could dramatically expand the Type 2 disease market.KYMRGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- Clinical pipeline expands with new dose levels, strong safety, and novel targets in immunology.KYMRUBS Targeted Protein Degradation Day 20243 Feb 2026
- Sanofi expanded KT-474 trials; KT-621 Phase 1 start imminent; $702.4M cash runway.KYMRQ2 20242 Feb 2026